Previous Article | Next Article ![]()
Infect Immun, February 1998, p. 474-479, Vol. 66, No. 2
CRC for Vaccine
Technology1 and
Department of
Microbiology and Immunology,
Received 26 June 1997/Returned for modification 22 September
1997/Accepted 3 November 1997
Corynebacterium pseudotuberculosis, a gram-positive
facultative intracellular bacterial pathogen, is the etiological agent of the economically important disease caseous lymphadenitis (CLA) in
both sheep and goats. Attenuated mutants of C. pseudotuberculosis have the potential to act as novel vaccines
against CLA and as veterinary vaccine vectors. In this report, we have
assessed the virulence of both aroQ and pld
mutants of C. pseudotuberculosis in sheep and concurrently
their capacity to act as vaccines against homologous challenge. The
results suggest that aroQ mutants of C. pseudotuberculosis are attenuated with regard to both lymph node
persistence and vaccination site reactogenicity. Immunologically, aroQ mutants failed to elicit detectable specific gamma
interferon (IFN-
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Vaccine Potential of Attenuated Mutants of
Corynebacterium pseudotuberculosis in Sheep
)-secreting lymphocytes and induced low levels of
antibodies to C. pseudotuberculosis culture supernatant
antigens. Following subcutaneous vaccination, the immune responses
induced by aroQ mutants did not protect sheep from
infection with the wild-type strain but did appear to reduce the
clinical severity of disease resulting from challenge. Conversely, an
attenuated C. pseudotuberculosis strain expressing an
enzymatically inactive phospholipase D exotoxin, when used as a
vaccine, elicited a protective immune response. Protection appeared to
correlate with in vivo persistence of the vaccine strain, the induction
of IFN-
-secreting lymphocytes, and relatively high levels of
antibodies to culture supernatant antigens. The results suggest that
aroQ mutants of C. pseudotuberculosis may be
overly attenuated for use as a CLA vaccines or as vaccine vectors.
*
Corresponding author. Mailing address: Department of
Microbiology, University of Melbourne, Parkville, Victoria, Australia 3052. Phone: 61 3 9344 5712. Fax: 61 3 9347 1540. E-mail:
r.strugnell{at}microbiology.unimelb.edu.au.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»